Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01935778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updatedv14
  2. Primary and study completion dates: Sep 2022 to Jun 30, 2028
    • Start date: Sep 2013 to Oct 2, 2013
    v13
  3. Study title expanded, about 1 wordv12
  4. Re-verified, no change to tracked fieldsv11
  5. Study title expanded, about 1 wordv10
Show 8 earlier versionsHide 8 earlier versions
  1. Collaborators expanded, about 14 wordsv9
  2. 6 versions Re-verified since Jun 26, 2015, no change to tracked fieldsv3-v8
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and combined therapy of Capecitabine and Oxaliplatin are currently accepted as a standard therapy among the AGC patients who were performed gastrectomy from the D2 surgery. However, many improvements will be needed in stage IIIB and IV. Combined chemotherapy of Docetaxel, Capecitabine, and Oxaliplatin may be considered as one of the best treatments for IIB and IV(M0) stage AGC patients who were performed gastrectomy.
Trial Details
NCT Number NCT01935778
Lead Sponsor Asan Medical Center
Collaborators: Seoul National University Bundang Hospital, Severance Hospital, Inha University Hospital, Hallym University Medical Center
Conditions
(from sponsor)		 Gastric Cancer, Adjuvant Chemotherapy, XO
Related terms Stomach Neoplasms
Enrollment 286 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov